137 related articles for article (PubMed ID: 24523452)
1. Controversies in neuro-oncology: does valganciclovir have a role in the treatment of high-grade gliomas?
Wen PY
Neuro Oncol; 2014 Mar; 16(3):329. PubMed ID: 24523452
[No Abstract] [Full Text] [Related]
2. Does valganciclovir have a role in glioblastoma therapy?
Cobbs CS
Neuro Oncol; 2014 Mar; 16(3):330-1. PubMed ID: 24523453
[No Abstract] [Full Text] [Related]
3. CMV infection and glioma, a highly controversial concept struggling in the clinical arena.
Wick W; Platten M
Neuro Oncol; 2014 Mar; 16(3):332-3. PubMed ID: 24523454
[No Abstract] [Full Text] [Related]
4. The legend of cytomegalovirus and glioblastoma lives on.
Weller M; Soffietti R; Brada M
Neuro Oncol; 2014 Jan; 16(1):166. PubMed ID: 24311642
[No Abstract] [Full Text] [Related]
5. Challenging cytomegalovirus data in glioblastoma.
Wick W; Wick A; Platten M
Neuro Oncol; 2014 Jan; 16(1):165. PubMed ID: 24353326
[No Abstract] [Full Text] [Related]
6. [Questionable effect of antiviral therapy in malignant brain tumors].
Kinhult S; Werlenius K; Hallbeck AL; Nyström PW; Männikkö V; Johansson M
Lakartidningen; 2014 Apr 29-May 13; 111(18-19):809. PubMed ID: 24855749
[No Abstract] [Full Text] [Related]
7. [Inconclusive data].
Kinhult S; Werlenius K; Hallbeck AL; Nyström PW; Männikkö V; Johansson M
Lakartidningen; 2014 Jul 2-15; 111(27-28):1192. PubMed ID: 25162111
[No Abstract] [Full Text] [Related]
8. Cytomegalovirus and glioblastoma: a review of evidence for their association and indications for testing and treatment.
Solomon IH; Ramkissoon SH; Milner DA; Folkerth RD
J Neuropathol Exp Neurol; 2014 Nov; 73(11):994-8. PubMed ID: 25289896
[TBL] [Abstract][Full Text] [Related]
9. Immortal time bias in retrospective analysis: is there a survival benefit in patients with glioblastoma who received prolonged treatment of adjuvant valganciclovir?
Liu CJ; Hu YW
Int J Cancer; 2014 Jul; 135(1):250-1. PubMed ID: 24338590
[No Abstract] [Full Text] [Related]
10. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study.
Stragliotto G; Rahbar A; Solberg NW; Lilja A; Taher C; Orrego A; Bjurman B; Tammik C; Skarman P; Peredo I; Söderberg-Nauclér C
Int J Cancer; 2013 Sep; 133(5):1204-13. PubMed ID: 23404447
[TBL] [Abstract][Full Text] [Related]
11. Survival in patients with glioblastoma receiving valganciclovir.
Söderberg-Nauclér C; Rahbar A; Stragliotto G
N Engl J Med; 2013 Sep; 369(10):985-6. PubMed ID: 24004141
[No Abstract] [Full Text] [Related]
12. Valganciclovir versus IV ganciclovir for therapy of cytomegalovirus viremia: has victory been achieved?
Avery RK
Am J Transplant; 2007 Sep; 7(9):2062-3. PubMed ID: 17697259
[No Abstract] [Full Text] [Related]
13. VIGAS and beyond: the impact of HCMV-infection and its treatment in glioblastoma.
Ottenhausen M; Bodhinayake I; Schaefer PM; Boockvar JA
Neurosurgery; 2014 Apr; 74(4):N17-8. PubMed ID: 24642991
[No Abstract] [Full Text] [Related]
14. Ganciclovir concentrations in the cerebral extracellular space after valganciclovir treatment; a case study.
Peredo I; Helldén A; Wolmer-Solberg N; Pohanka A; Stragliotto G; Rahbar A; Ståhle L; Bellander BM; Söderberg-Nauclér C
BMJ Case Rep; 2015 Dec; 2015():. PubMed ID: 26670887
[TBL] [Abstract][Full Text] [Related]
15. Use of Cox regression with treatment status as a time-dependent covariate to re-analyze survival benefit excludes immortal time bias effect in patients with glioblastoma who received prolonged adjuvant treatment with valganciclovir.
Söderberg-Naucler C; Peredo I; Rahbar A; Hansson F; Nordlund A; Stragliotto G
Int J Cancer; 2014 Jul; 135(1):248-9. PubMed ID: 24338548
[No Abstract] [Full Text] [Related]
16. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts.
Razonable RR; Paya CV
Expert Rev Anti Infect Ther; 2004 Feb; 2(1):27-41. PubMed ID: 15482169
[TBL] [Abstract][Full Text] [Related]
17. [Valganciclovir. Oral treatment of Cytomegalovirus infections].
Kroes AC
Ned Tijdschr Geneeskd; 2004 Jun; 148(25):1236-8. PubMed ID: 15301386
[TBL] [Abstract][Full Text] [Related]
18. Valganciclovir in patients with glioblastoma.
Hellstrand K; Martner A; Bergström T
N Engl J Med; 2013 Nov; 369(21):2066. PubMed ID: 24256397
[No Abstract] [Full Text] [Related]
19. Valganciclovir in patients with glioblastoma.
Söderberg-Nauclér C; Peredo I; Stragliotto G
N Engl J Med; 2013 Nov; 369(21):2066-7. PubMed ID: 24256396
[No Abstract] [Full Text] [Related]
20. Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host.
Freeman RB
Expert Opin Pharmacother; 2004 Sep; 5(9):2007-16. PubMed ID: 15330737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]